FI3920939T3 - Kimeerisiä anigeenireseptori-modifioituja soluja hoitamaan CLDN6-ekspressoivia syöpiä - Google Patents
Kimeerisiä anigeenireseptori-modifioituja soluja hoitamaan CLDN6-ekspressoivia syöpiä Download PDFInfo
- Publication number
- FI3920939T3 FI3920939T3 FIEP20702482.9T FI20702482T FI3920939T3 FI 3920939 T3 FI3920939 T3 FI 3920939T3 FI 20702482 T FI20702482 T FI 20702482T FI 3920939 T3 FI3920939 T3 FI 3920939T3
- Authority
- FI
- Finland
- Prior art keywords
- kos
- expansion
- cldn6
- treatment
- antigen receptor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 102100023915 Insulin Human genes 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 1
- 241000751119 Mila <angiosperm> Species 0.000 claims 1
- 241000750004 Nestor meridionalis Species 0.000 claims 1
- 230000002745 absorbent Effects 0.000 claims 1
- 239000002250 absorbent Substances 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 claims 1
- 239000004744 fabric Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 108700008259 iodoHis(3)- neurokinin A Proteins 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 235000019988 mead Nutrition 0.000 claims 1
- 210000002418 meninge Anatomy 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4264—Cancer antigens from embryonic or fetal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019053156 | 2019-02-08 | ||
| PCT/EP2020/052867 WO2020161186A1 (en) | 2019-02-08 | 2020-02-05 | Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3920939T3 true FI3920939T3 (fi) | 2025-01-03 |
Family
ID=69374312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20702482.9T FI3920939T3 (fi) | 2019-02-08 | 2020-02-05 | Kimeerisiä anigeenireseptori-modifioituja soluja hoitamaan CLDN6-ekspressoivia syöpiä |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20220184119A1 (enExample) |
| EP (2) | EP3920939B1 (enExample) |
| JP (2) | JP7663500B2 (enExample) |
| KR (1) | KR20210124237A (enExample) |
| CN (1) | CN113727720A (enExample) |
| AU (1) | AU2020217868A1 (enExample) |
| BR (1) | BR112021015429A2 (enExample) |
| CA (1) | CA3129140A1 (enExample) |
| CL (1) | CL2021002067A1 (enExample) |
| CO (1) | CO2021010347A2 (enExample) |
| CU (1) | CU20210067A7 (enExample) |
| DK (1) | DK3920939T3 (enExample) |
| ES (1) | ES3002958T3 (enExample) |
| FI (1) | FI3920939T3 (enExample) |
| HR (1) | HRP20250016T1 (enExample) |
| HU (1) | HUE070174T2 (enExample) |
| IL (1) | IL285122A (enExample) |
| LT (1) | LT3920939T (enExample) |
| MX (1) | MX2021009507A (enExample) |
| PL (1) | PL3920939T3 (enExample) |
| PT (1) | PT3920939T (enExample) |
| RS (1) | RS66364B1 (enExample) |
| SG (1) | SG11202108339TA (enExample) |
| SI (1) | SI3920939T1 (enExample) |
| SM (1) | SMT202500012T1 (enExample) |
| WO (1) | WO2020161186A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021129927A1 (en) * | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
| WO2024046572A1 (en) * | 2022-09-01 | 2024-03-07 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
| US20250025505A1 (en) * | 2021-12-09 | 2025-01-23 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
| CN114478802B (zh) * | 2022-01-28 | 2023-05-26 | 郑州大学 | 一种嵌合抗原受体及其应用 |
| CN114410588B (zh) * | 2022-01-29 | 2022-11-04 | 西安电子科技大学 | 一种α1β1整合素依赖增强型CAR巨噬细胞及其制备方法和应用 |
| CN119654342B (zh) * | 2022-07-28 | 2025-07-18 | 乐普创一生物科技（上海）有限公司 | 抗MerTK抗体及其用途 |
| KR20250046264A (ko) * | 2022-07-29 | 2025-04-02 | 레전드 바이오테크 아일랜드 리미티드 | 클라우딘6 겹합 모이어티 및 이의 용도 |
| CN120225555A (zh) * | 2022-10-25 | 2025-06-27 | 恺兴生命科技(上海)有限公司 | 抗体及其应用 |
| WO2025184170A1 (en) | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Methods and compositions for improving t cell function in an immunosuppressive environment |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| RU2714902C2 (ru) | 2013-12-19 | 2020-02-20 | Новартис Аг | Химерные рецепторы антигена против мезотелина человека и их применение |
| RS58627B2 (sr) * | 2014-04-01 | 2022-06-30 | Biontech Cell&Gene Therapies Gmbh | Klaudin-6-specifični imuno receptori i t-ćelijski epitopi |
| MA40921A (fr) | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |
| CN106146666B (zh) | 2015-03-26 | 2019-09-06 | 科济生物医药（上海）有限公司 | 靶向cldn6的免疫效应细胞及其制备方法和应用 |
| WO2016180467A1 (en) | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
| KR20200055037A (ko) * | 2017-09-19 | 2020-05-20 | 메사추세츠 인스티튜트 오브 테크놀로지 | 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도 |
| CN109206524B (zh) * | 2018-09-25 | 2022-04-05 | 山东兴瑞生物科技有限公司 | 抗Claudin18A2嵌合抗原受体、其修饰的T细胞及T细胞制备方法和用途 |
-
2020
- 2020-02-05 EP EP20702482.9A patent/EP3920939B1/en active Active
- 2020-02-05 CN CN202080026088.8A patent/CN113727720A/zh active Pending
- 2020-02-05 FI FIEP20702482.9T patent/FI3920939T3/fi active
- 2020-02-05 SG SG11202108339TA patent/SG11202108339TA/en unknown
- 2020-02-05 KR KR1020217024706A patent/KR20210124237A/ko active Pending
- 2020-02-05 BR BR112021015429-9A patent/BR112021015429A2/pt unknown
- 2020-02-05 LT LTEPPCT/EP2020/052867T patent/LT3920939T/lt unknown
- 2020-02-05 PT PT207024829T patent/PT3920939T/pt unknown
- 2020-02-05 SI SI202030558T patent/SI3920939T1/sl unknown
- 2020-02-05 CA CA3129140A patent/CA3129140A1/en active Pending
- 2020-02-05 EP EP24208680.9A patent/EP4501351A3/en active Pending
- 2020-02-05 WO PCT/EP2020/052867 patent/WO2020161186A1/en not_active Ceased
- 2020-02-05 US US17/310,463 patent/US20220184119A1/en active Pending
- 2020-02-05 JP JP2021546261A patent/JP7663500B2/ja active Active
- 2020-02-05 MX MX2021009507A patent/MX2021009507A/es unknown
- 2020-02-05 HR HRP20250016TT patent/HRP20250016T1/hr unknown
- 2020-02-05 CU CU2021000067A patent/CU20210067A7/es unknown
- 2020-02-05 PL PL20702482.9T patent/PL3920939T3/pl unknown
- 2020-02-05 DK DK20702482.9T patent/DK3920939T3/da active
- 2020-02-05 ES ES20702482T patent/ES3002958T3/es active Active
- 2020-02-05 AU AU2020217868A patent/AU2020217868A1/en active Pending
- 2020-02-05 SM SM20250012T patent/SMT202500012T1/it unknown
- 2020-02-05 RS RS20250008A patent/RS66364B1/sr unknown
- 2020-02-05 HU HUE20702482A patent/HUE070174T2/hu unknown
-
2021
- 2021-07-25 IL IL285122A patent/IL285122A/en unknown
- 2021-08-05 CO CONC2021/0010347A patent/CO2021010347A2/es unknown
- 2021-08-05 CL CL2021002067A patent/CL2021002067A1/es unknown
-
2024
- 2024-12-26 JP JP2024230070A patent/JP2025060882A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4501351A3 (en) | 2025-05-07 |
| WO2020161186A1 (en) | 2020-08-13 |
| US20220184119A1 (en) | 2022-06-16 |
| CA3129140A1 (en) | 2020-08-13 |
| JP2022520059A (ja) | 2022-03-28 |
| SG11202108339TA (en) | 2021-08-30 |
| SI3920939T1 (sl) | 2025-03-31 |
| KR20210124237A (ko) | 2021-10-14 |
| RS66364B1 (sr) | 2025-01-31 |
| AU2020217868A1 (en) | 2021-08-12 |
| JP2025060882A (ja) | 2025-04-10 |
| IL285122A (en) | 2021-09-30 |
| PL3920939T3 (pl) | 2025-02-17 |
| LT3920939T (lt) | 2025-01-10 |
| DK3920939T3 (da) | 2025-01-13 |
| HUE070174T2 (hu) | 2025-05-28 |
| SMT202500012T1 (it) | 2025-03-12 |
| PT3920939T (pt) | 2025-01-08 |
| CU20210067A7 (es) | 2022-03-07 |
| EP4501351A2 (en) | 2025-02-05 |
| BR112021015429A2 (pt) | 2021-10-05 |
| MX2021009507A (es) | 2021-09-08 |
| EP3920939A1 (en) | 2021-12-15 |
| ES3002958T3 (en) | 2025-03-10 |
| CN113727720A (zh) | 2021-11-30 |
| JP7663500B2 (ja) | 2025-04-16 |
| CO2021010347A2 (es) | 2022-01-17 |
| EP3920939B1 (en) | 2024-11-13 |
| HRP20250016T1 (hr) | 2025-03-14 |
| CL2021002067A1 (es) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3920939T3 (fi) | Kimeerisiä anigeenireseptori-modifioituja soluja hoitamaan CLDN6-ekspressoivia syöpiä | |
| Wu et al. | Disturbance observer based robust mixed H2/H∞ fuzzy tracking control for hypersonic vehicles | |
| IL317505A (en) | CRISPR-directed delivery platforms | |
| EP1030166A3 (de) | Verfahren zur Navigation eines Objekts | |
| BR9200790A (pt) | Sequencia de adn vegetal da zona de transito,gen quimerico,vetor para transformacao de plantas,agrobacterium sp.,celula vegetal transformada,planta transformada e processo de producao de gen quimerico | |
| US9663219B2 (en) | Method and system for controlling the flight of an aircraft | |
| KR20180057173A (ko) | 이족 보행 로봇의 안정된 보행 제어를 위해 단순화된 로봇의 모델링 방법 | |
| Kazemy et al. | Finite-frequency H∞ control for offshore platforms subject to parametric model uncertainty and practical hard constraints | |
| CN113297745B (zh) | 一种基于短弧拟合位置的双弧段轨道改进方法 | |
| Koo et al. | An improved digital redesign for sampled-data fuzzy control systems: Fuzzy Lyapunov function approach | |
| EP0857765A3 (de) | Stabilisatoren für Pulverlacke | |
| Zhang et al. | Guidance algorithm for impact time, angle, and acceleration control under varying velocity condition | |
| Liu et al. | Comparative study of adaptive trajectory tracking controller for four-wheel mobile robot with prescribed-prediction performance | |
| CN103064419A (zh) | 一种中高轨道卫星比例式遥控指令的延时执行方法 | |
| Hyde | Biprobability approach to CP phase degeneracy from non-standard neutrino interactions | |
| CN104958913A (zh) | 基于条形码控制的玩具 | |
| KONG et al. | Adsorption and leaching behavior of seven pesticides in three different soils | |
| Ramirez-Martinez et al. | Mobile robot adaptive trajectory control: Non-linear path model inverse transformation for model reference | |
| Frahm | Mosses and liverworts of the Western Ghats, India–a picture book | |
| Sadig et al. | A new approach based on constrained motion to control of a moving base manipulator | |
| Singh et al. | Field-of-View and Input Constrained Impact Time Guidance Against Stationary Targets | |
| CN106249913A (zh) | 一种文字一体式输入且可拆卸式清除的方法 | |
| Bhattacharyya | Piezometric Efficiency in an Orthodox Gun | |
| Krauthammer | The End of Arms Control. | |
| Abulafia | Abu Qurinat |